# Ipamorelin Research: Mechanism, Human Data, and the Combination Evidence > Ipamorelin research in depth: GHS-R1a mechanism, the human PK and failed Phase 2 trial, rodent bone and body-composition data, and the separate CJC-1295 evidence behind the stack. Mechanism, pharmacokinetics, the one human efficacy trial, and the GHRH-analog evidence the stack actually leans on. ## Before the details Here is the Ipamorelin research in plain terms before the technical version. Ipamorelin is a five-amino-acid peptide that flips one specific switch — the ghrelin receptor on the pituitary gland — to release a pulse of growth hormone (GH). Its claim to fame is that it does this without the side spillover (cortisol, prolactin) that troubled earlier peptides in its class [1]. The animal data are reasonably consistent: it pulses GH, grows bone in young rats, and shifts body fat. The human data are sparse — one study of how the drug moves through the body [2], and one efficacy trial that failed [3]. Because researchers usually want a bigger, longer GH signal, they pair ipamorelin with a longer-acting partner, CJC-1295, that works through a different receptor. Below, each major finding gets its own section, the monotherapy data are kept separate from the combination data, and the limits are stated plainly. ## What is ipamorelin peptide? Ipamorelin is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular weight ~712 Da, CAS 170851-70-4. It was built by trimming a central dipeptide out of the older peptide GHRP-1, and two of its building blocks are D-form (mirror-image) amino acids that make it resist enzymatic breakdown. Mechanistically it is a selective agonist of GHS-R1a, the ghrelin / growth-hormone-secretagogue receptor [1]. It is not an endogenous human peptide; it mimics ghrelin at that receptor. ## Mechanism: one receptor, one clean pulse Ipamorelin binds GHS-R1a on pituitary somatotrophs (the GH-making cells), triggering the Gq/PLC pathway, a rise in intracellular calcium, and a pulse of GH release. The signature finding — and the reason the molecule exists — is selectivity: in its 1998 characterization it released GH as potently as GHRP-6 but, unlike GHRP-6, it did not raise ACTH or cortisol above the level seen with GHRH even at more than 200-fold its GH ED50 [1]. The receptor it uses is distinct from and complementary to the GHRH receptor, which is the entire mechanistic basis for combining it with GHRH analogs. Beyond the pituitary, GHS-R1a signaling also reaches enteric neurons (driving gut motility) and pancreatic islet cells, where ipamorelin showed a direct, GH-independent insulin-releasing effect in rat tissue [13]. ## Human pharmacokinetics and the one efficacy trial The human dataset is small and worth stating precisely. Population PK/PD modeling in healthy male volunteers (n=8 per dose level; five 15-minute IV infusions of 4.21–140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg; the GH response was a single discrete pulse peaking around 40 minutes after dosing [2]. Efficacy in humans was tested once, for postoperative ileus. In that Phase 2 RCT (NCT00672074), 114 adults undergoing bowel resection received 0.03 mg/kg IV twice daily for up to 7 days. The trial missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% on placebo — no ipamorelin-specific safety signal in that short window, but no demonstrated benefit either [3]. No Phase 3 trial followed. ## Preclinical efficacy: bone, body composition, and gut The animal record is more encouraging and more consistent than the human one. Subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate of adult female rats from 42 µm/day on vehicle to 44, 50, and 52 µm/day — notably with no change in total IGF-1 or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect [4]. Body composition shifts too, and partly through a non-GH route: twice-daily subcutaneous ipamorelin for two weeks produced a small (~15%) body-weight increase in both GH-deficient and GH-intact mice, with fat-pad weight and serum leptin up in both genotypes — evidence that part of the adiposity effect is GH-independent and runs through direct ghrelin signaling [14]. The most recent in-vivo study, a 2024 ferret experiment, found that intraperitoneal ipamorelin (1–3 mg/kg) cut cisplatin-induced body-weight loss by about 24% in the delayed phase, though it had no anti-emetic effect — a peripheral, weight-protective action without nausea control [5]. ## The combination evidence (and whose data it is) The case for stacking ipamorelin with a GHRH analog is built almost entirely from the partner's data. CJC-1295, a long-acting GHRH analog, produced dose-dependent 2- to 10-fold GH increases for six-plus days and 1.5- to 3-fold sustained IGF-1 elevation after a single subcutaneous dose in healthy adults, while preserving pulsatile GH secretion [7]. Pulsatile GH release persisted even under continuous GHRH-pathway stimulation by CJC-1295 [8], and further analysis characterized the durable GH/IGF-1 axis activation [9]. Every one of those studies is on CJC-1295, not ipamorelin. An observational report in hypogonadal men found that combined GHS therapy raised serum IGF-1 [10], and a 2020 andrology review situated the whole GHS class against the gap between marketed use and approved indications [11]. The combination of ipamorelin and CJC-1295 has never been tested as a single product in a controlled trial for any outcome. ## Is ipamorelin FDA approved? No. Ipamorelin has never been approved as a drug by the FDA — or by any other regulator, anywhere — for any indication [11]. Its only clinical program (postoperative ileus) reached Phase 2 and stopped after the trial failed [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access [11]. It is sold only as a research chemical. ## Recent research (2024–2026) The newest literature is mostly review-level and cautionary. A 2026 structured narrative review of injectable peptides in sports medicine classed ipamorelin as an investigational GH-axis secretagogue with no reproducible human evidence for musculoskeletal outcomes, recommending use be confined to rigorous research protocols [16]. A 2026 critical review of peptide and peptide-analog drugs in sport flagged ipamorelin as widely promoted for fat metabolism and body composition, with serious safety concerns in uncontrolled use and an expanding WADA detection framework [17]. And a 2024 fish study showed ipamorelin acetate dose-dependently elevated LH and 11-ketotestosterone and stimulated germ-cell development in tilapia — cross-species evidence that ghrelin-receptor agonism can activate the reproductive (HPG) axis [18]. --- An editorial digest of the ipamorelin literature and the GHRH-analog stacks it is studied beside — single-peptide findings kept apart from combination claims, and nothing here dosed, compounded, prescribed, or sold.